Market Overview
The global immunohematology market was valued at USD 2.0 Billion in 2024 and is projected to reach USD 2.9 Billion by 2033, growing at a CAGR of 4% during the forecast period 2025-2033. This growth is driven by rising demand for advanced blood testing and compatibility solutions, advancements in diagnostic technologies, and expanding healthcare infrastructure. North America holds the largest market share due to advanced healthcare systems and significant R&D investments.
Study Assumption Years
• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033
Immunohematology Market Key Takeaways
• The global immunohematology market size was valued at USD 2.0 Billion in 2024.
• The market is expected to grow at a CAGR of 4% during 2025-2033.
• The forecast period for the market is 2025-2033.
• North America dominates with over 40.2% market share in 2024, driven by advanced healthcare infrastructure and strong R&D.
• Reagents and consumables represent the largest product segment in 2024, accounting for around 65.5% of the market.
• Polymerase chain reaction leads the technology segment with approximately 38.5% share.
• HIV is the leading application segment due to its high prevalence and government initiatives.
Sample Request Link:
https://www.imarcgroup.com/Immunohematology-Market/requestsample
Market Growth Factors
Several factors such as the increasing demand for advanced blood screening and compatibility testing procedures, the growing prevalence of chronic diseases, and the increasing volume of surgical procedures worldwide are driving the growth of the immunohematology market. Increased demand for blood typing, cross-matching, and antibody detection procedures for ensuring patient safety during blood transfusion procedures and organ transplantation further supports this market growth. The introduction of automated analyzers and molecular diagnostics to increase the accuracy and efficiency of testing increased uptake in clinical laboratories.
An increase in healthcare settings in emerging economies and the various benefits of safe blood transfusion practices worldwide are anticipated to drive growth and widen the blood screening market. The launch of new products for use in genetic research, such as Thermo Fisher Scientific's Axiom PangenomiX Array, is expected to provide an opportunity for market growth.
Another factor for the growth of the market is the rising prevalence of hematological disorders such as leukemia across the globe. Also, millions of blood donations are done throughout the globe every year in blood donation centers, driving the market. Another factor driving market growth is the need for prompt and accurate diagnostics in hospitals and blood banks.
Market Segmentation
By Product
• Analyzing Systems
• Reagents and Consumables: Representing approximately 65.5% of the market in 2024, these products are crucial for blood typing, antibody screening, and crossmatching, which are essential for transfusion safety and diagnostic accuracy in laboratories, blood banks, and hospitals.
By Technology
• Biochips
• Gel Cards
• Microplates
• Polymerase Chain Reaction: Leading with around 38.5% market share in 2024, PCR is vital for precise DNA and RNA amplification, supporting infectious disease detection, genetic mutation analysis, and cancer marker identification.
• Erythrocyte-Magnetized Technology
• Others
By Application
• Blood-Related Diseases
• HIV: The largest application segment in 2024 due to its significance in diagnostics, treatment monitoring, and government-backed eradication initiatives.
• Hepatitis
• Blood Transfusion
• Others
By End-User
• Hospitals: Leading with about 23.8% of the market share in 2024, hospitals are primary centers for diagnostics and treatment, benefiting from high patient volumes and advanced technologies.
• Blood Banks
• Diagnostic Laboratories
• Others
Regional Insights
North America dominates the immunohematology market with over 40.2% share in 2024. This regional leadership is supported by advanced healthcare infrastructures, significant investments in R&D, and high technology adoption rates. The presence of key industry players, government healthcare funding, and increasing demand for cutting-edge medical devices further consolidate North America’s market position. Chronic disease prevalence and stringent regulatory frameworks also promote adoption of advanced immunohematology solutions.
Recent Developments & News
In November 2024, T&D announced plans to launch its Centus 5-Part Hematology Analyzer HA-500 at Medica 2024, aiming to improve clinical lab efficiency and accuracy. In September 2024, Zoetis Inc. released the Vetscan OptiCell™, an AI-powered hematology analyzer for veterinary Complete Blood Count analysis in the U.S., enhancing workflow and patient outcomes. June 2024 saw HORIBA expanding its hematology product range with new models offering rapid combined testing capabilities. Additionally, in January 2024, Agappe launched the HX series haematology analyzers and the Mispa i200 Immunology CLIA analyzer in India, aimed at faster, more accurate blood testing.
Key Players
Abbott
Antisel
BD (Becton Dickinson and Company)
Beckman Coulter Inc. (Danaher Corporation)
Bio-Rad Laboratories Inc.
F. Hoffmann-La Roche Ltd.
Grifols S.A.
Merck KGaA
MTC Invitro Diagnostics AG
Ortho-Clinical Diagnostics Inc (The Carlyle Group)
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request For Customization: https://www.imarcgroup.com/request?type=report&id=2256&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302
Comments (0)